BSE Live
Mar 30, 16:01Prev. Close
31.93
Open Price
31.41
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Shukra Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.22 | 16.93 | 26.21 | 4.79 | 0.22 | |
| Diluted EPS (Rs.) | 0.22 | 16.93 | 26.21 | 4.79 | 0.22 | |
| Cash EPS (Rs.) | 0.29 | 18.81 | 15.95 | 15.41 | 9.63 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 1.44 | 52.65 | 64.63 | 104.43 | 99.63 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 1.44 | 52.65 | 64.63 | 104.43 | 99.63 | |
| Dividend / Share(Rs.) | 0.01 | 1.00 | 0.50 | 0.50 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.74 | 68.12 | 150.31 | 130.84 | 71.51 | |
| PBDIT/Share (Rs.) | 0.39 | 20.30 | 16.76 | 18.95 | 11.50 | |
| PBIT/Share (Rs.) | 0.32 | 18.42 | 12.07 | 8.33 | 2.09 | |
| PBT/Share (Rs.) | 0.30 | 18.16 | 11.35 | 6.50 | 0.63 | |
| Net Profit/Share (Rs.) | 0.22 | 16.93 | 11.26 | 4.79 | 0.22 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 51.97 | 29.79 | 11.15 | 14.48 | 16.07 | |
| PBIT Margin (%) | 42.75 | 27.04 | 8.02 | 6.36 | 2.91 | |
| PBT Margin (%) | 40.92 | 26.66 | 7.54 | 4.96 | 0.87 | |
| Net Profit Margin (%) | 29.38 | 24.85 | 7.48 | 3.66 | 0.30 | |
| Return on Networth / Equity (%) | 15.23 | 32.16 | 17.41 | 4.59 | 0.21 | |
| Return on Capital Employed (%) | 20.04 | 31.66 | 14.54 | 5.73 | 1.14 | |
| Return on Assets (%) | 11.03 | 23.81 | 5.87 | 2.13 | 0.09 | |
| Total Debt/Equity (X) | 0.07 | 0.05 | 0.20 | 0.21 | 0.63 | |
| Asset Turnover Ratio (%) | 0.40 | 0.98 | 1.07 | 0.59 | 0.33 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.79 | 3.97 | 1.25 | 1.27 | 2.46 | |
| Quick Ratio (X) | 3.21 | 3.81 | 1.17 | 0.95 | 2.19 | |
| Inventory Turnover Ratio (X) | 5.31 | 4.89 | 3.19 | 3.93 | 1.93 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.37 | 1.77 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.34 | 1.25 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 99.63 | 98.23 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 99.66 | 98.75 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 948.82 | 350.65 | 19.48 | 12.75 | 16.23 | |
| EV/Net Operating Revenue (X) | 29.12 | 4.70 | 0.33 | 0.62 | 1.45 | |
| EV/EBITDA (X) | 56.02 | 15.78 | 2.97 | 4.30 | 9.02 | |
| MarketCap/Net Operating Revenue (X) | 29.36 | 4.79 | 0.31 | 0.46 | 0.62 | |
| Retention Ratios (%) | 0.00 | 99.62 | 98.22 | 0.00 | 0.00 | |
| Price/BV (X) | 15.23 | 6.20 | 0.73 | 0.58 | 0.45 | |
| Price/Net Operating Revenue | 29.36 | 4.79 | 0.31 | 0.46 | 0.62 | |
| Earnings Yield | 0.01 | 0.05 | 0.24 | 0.08 | 0.00 |
10.02.2026
Shukra Pharma Consolidated December 2025 Net Sales at Rs 39.13 crore, up 269.74% Y-o-Y
09.02.2026
Shukra Pharma Standalone December 2025 Net Sales at Rs 39.13 crore, up 269.74% Y-o-Y
24.11.2025
Shukra Pharma Standalone September 2025 Net Sales at Rs 5.88 crore, up 5.8% Y-o-Y
12.06.2025
Shukra Pharma Standalone March 2025 Net Sales at Rs 13.27 crore, up 21.92% Y-o-Y
31.03.2026
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
29.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth